nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—ABCC2—Vincristine—lymphatic system cancer	0.278	0.434	CbGbCtD
Eprosartan—CYP2C9—Teniposide—lymphatic system cancer	0.194	0.303	CbGbCtD
Eprosartan—ABCC2—Methotrexate—lymphatic system cancer	0.168	0.263	CbGbCtD
Eprosartan—Haematuria—Bleomycin—lymphatic system cancer	0.00158	0.00438	CcSEcCtD
Eprosartan—Pruritus—Mechlorethamine—lymphatic system cancer	0.00157	0.00436	CcSEcCtD
Eprosartan—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00157	0.00435	CcSEcCtD
Eprosartan—Anorexia—Teniposide—lymphatic system cancer	0.00156	0.00433	CcSEcCtD
Eprosartan—Cough—Fludarabine—lymphatic system cancer	0.00154	0.00427	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00153	0.00426	CcSEcCtD
Eprosartan—Hypotension—Teniposide—lymphatic system cancer	0.00153	0.00424	CcSEcCtD
Eprosartan—Gingivitis—Methotrexate—lymphatic system cancer	0.00152	0.00423	CcSEcCtD
Eprosartan—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00152	0.00422	CcSEcCtD
Eprosartan—Myalgia—Fludarabine—lymphatic system cancer	0.0015	0.00416	CcSEcCtD
Eprosartan—Arthralgia—Fludarabine—lymphatic system cancer	0.0015	0.00416	CcSEcCtD
Eprosartan—Discomfort—Fludarabine—lymphatic system cancer	0.00148	0.00411	CcSEcCtD
Eprosartan—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00147	0.00407	CcSEcCtD
Eprosartan—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00146	0.00405	CcSEcCtD
Eprosartan—Dyspnoea—Teniposide—lymphatic system cancer	0.00146	0.00405	CcSEcCtD
Eprosartan—Depression—Carmustine—lymphatic system cancer	0.00144	0.00399	CcSEcCtD
Eprosartan—Decreased appetite—Teniposide—lymphatic system cancer	0.00142	0.00395	CcSEcCtD
Eprosartan—Renal failure—Carmustine—lymphatic system cancer	0.00142	0.00394	CcSEcCtD
Eprosartan—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00141	0.00393	CcSEcCtD
Eprosartan—Vomiting—Mechlorethamine—lymphatic system cancer	0.00141	0.00392	CcSEcCtD
Eprosartan—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00141	0.00391	CcSEcCtD
Eprosartan—Urinary tract infection—Carmustine—lymphatic system cancer	0.0014	0.00389	CcSEcCtD
Eprosartan—Rash—Mechlorethamine—lymphatic system cancer	0.0014	0.00388	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.0014	0.00388	CcSEcCtD
Eprosartan—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0014	0.00388	CcSEcCtD
Eprosartan—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00139	0.00386	CcSEcCtD
Eprosartan—Depression—Vincristine—lymphatic system cancer	0.00137	0.00381	CcSEcCtD
Eprosartan—Anorexia—Fludarabine—lymphatic system cancer	0.00137	0.0038	CcSEcCtD
Eprosartan—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00136	0.00377	CcSEcCtD
Eprosartan—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00135	0.00375	CcSEcCtD
Eprosartan—Feeling abnormal—Teniposide—lymphatic system cancer	0.00135	0.00374	CcSEcCtD
Eprosartan—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00134	0.00371	CcSEcCtD
Eprosartan—Chills—Bleomycin—lymphatic system cancer	0.00133	0.0037	CcSEcCtD
Eprosartan—Renal failure—Mitoxantrone—lymphatic system cancer	0.00132	0.00366	CcSEcCtD
Eprosartan—Nausea—Mechlorethamine—lymphatic system cancer	0.00132	0.00366	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00131	0.00364	CcSEcCtD
Eprosartan—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.0013	0.00362	CcSEcCtD
Eprosartan—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.0013	0.00362	CcSEcCtD
Eprosartan—Urticaria—Teniposide—lymphatic system cancer	0.0013	0.00361	CcSEcCtD
Eprosartan—Herpes simplex—Methotrexate—lymphatic system cancer	0.0013	0.0036	CcSEcCtD
Eprosartan—Body temperature increased—Teniposide—lymphatic system cancer	0.00129	0.00359	CcSEcCtD
Eprosartan—Abdominal pain—Teniposide—lymphatic system cancer	0.00129	0.00359	CcSEcCtD
Eprosartan—Paraesthesia—Fludarabine—lymphatic system cancer	0.00129	0.00358	CcSEcCtD
Eprosartan—Dyspnoea—Fludarabine—lymphatic system cancer	0.00128	0.00356	CcSEcCtD
Eprosartan—Haematuria—Mitoxantrone—lymphatic system cancer	0.00128	0.00355	CcSEcCtD
Eprosartan—Oedema peripheral—Carmustine—lymphatic system cancer	0.00128	0.00354	CcSEcCtD
Eprosartan—Dyspepsia—Fludarabine—lymphatic system cancer	0.00127	0.00351	CcSEcCtD
Eprosartan—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00126	0.00349	CcSEcCtD
Eprosartan—Decreased appetite—Fludarabine—lymphatic system cancer	0.00125	0.00347	CcSEcCtD
Eprosartan—Visual impairment—Carmustine—lymphatic system cancer	0.00125	0.00347	CcSEcCtD
Eprosartan—Fatigue—Fludarabine—lymphatic system cancer	0.00124	0.00344	CcSEcCtD
Eprosartan—Pain—Fludarabine—lymphatic system cancer	0.00123	0.00341	CcSEcCtD
Eprosartan—Constipation—Fludarabine—lymphatic system cancer	0.00123	0.00341	CcSEcCtD
Eprosartan—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00123	0.0034	CcSEcCtD
Eprosartan—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00121	0.00335	CcSEcCtD
Eprosartan—Hypersensitivity—Teniposide—lymphatic system cancer	0.00121	0.00335	CcSEcCtD
Eprosartan—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.0012	0.00333	CcSEcCtD
Eprosartan—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00119	0.00332	CcSEcCtD
Eprosartan—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00118	0.00329	CcSEcCtD
Eprosartan—Asthenia—Teniposide—lymphatic system cancer	0.00117	0.00326	CcSEcCtD
Eprosartan—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00117	0.00324	CcSEcCtD
Eprosartan—Malaise—Bleomycin—lymphatic system cancer	0.00116	0.00323	CcSEcCtD
Eprosartan—Pruritus—Teniposide—lymphatic system cancer	0.00116	0.00321	CcSEcCtD
Eprosartan—Cystitis—Methotrexate—lymphatic system cancer	0.00115	0.0032	CcSEcCtD
Eprosartan—Body temperature increased—Fludarabine—lymphatic system cancer	0.00114	0.00316	CcSEcCtD
Eprosartan—Cough—Bleomycin—lymphatic system cancer	0.00113	0.00313	CcSEcCtD
Eprosartan—Diarrhoea—Teniposide—lymphatic system cancer	0.00112	0.00311	CcSEcCtD
Eprosartan—Chest pain—Bleomycin—lymphatic system cancer	0.0011	0.00305	CcSEcCtD
Eprosartan—Myalgia—Bleomycin—lymphatic system cancer	0.0011	0.00305	CcSEcCtD
Eprosartan—Back pain—Carmustine—lymphatic system cancer	0.00109	0.00303	CcSEcCtD
Eprosartan—Discomfort—Bleomycin—lymphatic system cancer	0.00109	0.00302	CcSEcCtD
Eprosartan—Chills—Mitoxantrone—lymphatic system cancer	0.00108	0.003	CcSEcCtD
Eprosartan—Urine output increased—Methotrexate—lymphatic system cancer	0.00108	0.003	CcSEcCtD
Eprosartan—Bladder pain—Methotrexate—lymphatic system cancer	0.00108	0.003	CcSEcCtD
Eprosartan—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00106	0.00294	CcSEcCtD
Eprosartan—Tremor—Carmustine—lymphatic system cancer	0.00106	0.00293	CcSEcCtD
Eprosartan—Back pain—Vincristine—lymphatic system cancer	0.00104	0.00289	CcSEcCtD
Eprosartan—Vomiting—Teniposide—lymphatic system cancer	0.00104	0.00289	CcSEcCtD
Eprosartan—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00103	0.00287	CcSEcCtD
Eprosartan—Asthenia—Fludarabine—lymphatic system cancer	0.00103	0.00286	CcSEcCtD
Eprosartan—Rash—Teniposide—lymphatic system cancer	0.00103	0.00286	CcSEcCtD
Eprosartan—Dermatitis—Teniposide—lymphatic system cancer	0.00103	0.00286	CcSEcCtD
Eprosartan—Headache—Teniposide—lymphatic system cancer	0.00102	0.00285	CcSEcCtD
Eprosartan—Pruritus—Fludarabine—lymphatic system cancer	0.00102	0.00282	CcSEcCtD
Eprosartan—Back pain—Mitoxantrone—lymphatic system cancer	0.00101	0.00281	CcSEcCtD
Eprosartan—Anorexia—Bleomycin—lymphatic system cancer	0.001	0.00279	CcSEcCtD
Eprosartan—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000997	0.00277	CcSEcCtD
Eprosartan—Polyuria—Methotrexate—lymphatic system cancer	0.000988	0.00274	CcSEcCtD
Eprosartan—Hypotension—Bleomycin—lymphatic system cancer	0.000985	0.00273	CcSEcCtD
Eprosartan—Diarrhoea—Fludarabine—lymphatic system cancer	0.000984	0.00273	CcSEcCtD
Eprosartan—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000972	0.0027	CcSEcCtD
Eprosartan—Nausea—Teniposide—lymphatic system cancer	0.000972	0.0027	CcSEcCtD
Eprosartan—Vertigo—Vincristine—lymphatic system cancer	0.000967	0.00268	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00096	0.00267	CcSEcCtD
Eprosartan—Chest pain—Carmustine—lymphatic system cancer	0.00096	0.00266	CcSEcCtD
Eprosartan—Myalgia—Carmustine—lymphatic system cancer	0.00096	0.00266	CcSEcCtD
Eprosartan—Anxiety—Carmustine—lymphatic system cancer	0.000956	0.00266	CcSEcCtD
Eprosartan—Paraesthesia—Bleomycin—lymphatic system cancer	0.000946	0.00263	CcSEcCtD
Eprosartan—Malaise—Mitoxantrone—lymphatic system cancer	0.000945	0.00262	CcSEcCtD
Eprosartan—Dyspnoea—Bleomycin—lymphatic system cancer	0.00094	0.00261	CcSEcCtD
Eprosartan—Decreased appetite—Bleomycin—lymphatic system cancer	0.000916	0.00254	CcSEcCtD
Eprosartan—Myalgia—Vincristine—lymphatic system cancer	0.000916	0.00254	CcSEcCtD
Eprosartan—Cough—Mitoxantrone—lymphatic system cancer	0.000915	0.00254	CcSEcCtD
Eprosartan—Vomiting—Fludarabine—lymphatic system cancer	0.000914	0.00254	CcSEcCtD
Eprosartan—Rash—Fludarabine—lymphatic system cancer	0.000906	0.00252	CcSEcCtD
Eprosartan—Dermatitis—Fludarabine—lymphatic system cancer	0.000906	0.00251	CcSEcCtD
Eprosartan—Pain—Bleomycin—lymphatic system cancer	0.000901	0.0025	CcSEcCtD
Eprosartan—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000901	0.0025	CcSEcCtD
Eprosartan—Headache—Fludarabine—lymphatic system cancer	0.000901	0.0025	CcSEcCtD
Eprosartan—Tachycardia—Carmustine—lymphatic system cancer	0.000898	0.00249	CcSEcCtD
Eprosartan—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000892	0.00248	CcSEcCtD
Eprosartan—Chest pain—Mitoxantrone—lymphatic system cancer	0.000892	0.00248	CcSEcCtD
Eprosartan—Myalgia—Mitoxantrone—lymphatic system cancer	0.000892	0.00248	CcSEcCtD
Eprosartan—Anxiety—Mitoxantrone—lymphatic system cancer	0.000889	0.00247	CcSEcCtD
Eprosartan—Discomfort—Mitoxantrone—lymphatic system cancer	0.000882	0.00245	CcSEcCtD
Eprosartan—Anorexia—Carmustine—lymphatic system cancer	0.000877	0.00244	CcSEcCtD
Eprosartan—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000869	0.00241	CcSEcCtD
Eprosartan—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000867	0.00241	CcSEcCtD
Eprosartan—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00086	0.00239	CcSEcCtD
Eprosartan—Hypotension—Carmustine—lymphatic system cancer	0.00086	0.00239	CcSEcCtD
Eprosartan—Nausea—Fludarabine—lymphatic system cancer	0.000854	0.00237	CcSEcCtD
Eprosartan—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000849	0.00236	CcSEcCtD
Eprosartan—Shock—Mitoxantrone—lymphatic system cancer	0.000842	0.00234	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000838	0.00233	CcSEcCtD
Eprosartan—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000838	0.00233	CcSEcCtD
Eprosartan—Urticaria—Bleomycin—lymphatic system cancer	0.000837	0.00233	CcSEcCtD
Eprosartan—Anorexia—Vincristine—lymphatic system cancer	0.000837	0.00232	CcSEcCtD
Eprosartan—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000835	0.00232	CcSEcCtD
Eprosartan—Body temperature increased—Bleomycin—lymphatic system cancer	0.000833	0.00231	CcSEcCtD
Eprosartan—Insomnia—Carmustine—lymphatic system cancer	0.000832	0.00231	CcSEcCtD
Eprosartan—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000827	0.0023	CcSEcCtD
Eprosartan—Paraesthesia—Carmustine—lymphatic system cancer	0.000826	0.00229	CcSEcCtD
Eprosartan—Hypotension—Vincristine—lymphatic system cancer	0.000821	0.00228	CcSEcCtD
Eprosartan—Dyspnoea—Carmustine—lymphatic system cancer	0.00082	0.00228	CcSEcCtD
Eprosartan—Somnolence—Carmustine—lymphatic system cancer	0.000818	0.00227	CcSEcCtD
Eprosartan—Anorexia—Mitoxantrone—lymphatic system cancer	0.000815	0.00226	CcSEcCtD
Eprosartan—Ataxia—Methotrexate—lymphatic system cancer	0.000815	0.00226	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.0008	0.00222	CcSEcCtD
Eprosartan—Decreased appetite—Carmustine—lymphatic system cancer	0.0008	0.00222	CcSEcCtD
Eprosartan—Hypotension—Mitoxantrone—lymphatic system cancer	0.000799	0.00222	CcSEcCtD
Eprosartan—Insomnia—Vincristine—lymphatic system cancer	0.000794	0.00221	CcSEcCtD
Eprosartan—Paraesthesia—Vincristine—lymphatic system cancer	0.000789	0.00219	CcSEcCtD
Eprosartan—Pain—Carmustine—lymphatic system cancer	0.000787	0.00218	CcSEcCtD
Eprosartan—Constipation—Carmustine—lymphatic system cancer	0.000787	0.00218	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000779	0.00216	CcSEcCtD
Eprosartan—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000777	0.00216	CcSEcCtD
Eprosartan—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000768	0.00213	CcSEcCtD
Eprosartan—Decreased appetite—Vincristine—lymphatic system cancer	0.000764	0.00212	CcSEcCtD
Eprosartan—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000763	0.00212	CcSEcCtD
Eprosartan—Somnolence—Mitoxantrone—lymphatic system cancer	0.00076	0.00211	CcSEcCtD
Eprosartan—Feeling abnormal—Carmustine—lymphatic system cancer	0.000758	0.00211	CcSEcCtD
Eprosartan—Fatigue—Vincristine—lymphatic system cancer	0.000757	0.0021	CcSEcCtD
Eprosartan—Asthenia—Bleomycin—lymphatic system cancer	0.000756	0.0021	CcSEcCtD
Eprosartan—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000753	0.00209	CcSEcCtD
Eprosartan—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000752	0.00209	CcSEcCtD
Eprosartan—Pain—Vincristine—lymphatic system cancer	0.000751	0.00209	CcSEcCtD
Eprosartan—Constipation—Vincristine—lymphatic system cancer	0.000751	0.00209	CcSEcCtD
Eprosartan—Asthma—Methotrexate—lymphatic system cancer	0.000749	0.00208	CcSEcCtD
Eprosartan—Pruritus—Bleomycin—lymphatic system cancer	0.000746	0.00207	CcSEcCtD
Eprosartan—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000744	0.00206	CcSEcCtD
Eprosartan—Fatigue—Mitoxantrone—lymphatic system cancer	0.000737	0.00205	CcSEcCtD
Eprosartan—Pain—Mitoxantrone—lymphatic system cancer	0.000731	0.00203	CcSEcCtD
Eprosartan—Constipation—Mitoxantrone—lymphatic system cancer	0.000731	0.00203	CcSEcCtD
Eprosartan—Abdominal pain—Carmustine—lymphatic system cancer	0.000727	0.00202	CcSEcCtD
Eprosartan—Body temperature increased—Carmustine—lymphatic system cancer	0.000727	0.00202	CcSEcCtD
Eprosartan—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000718	0.00199	CcSEcCtD
Eprosartan—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000705	0.00196	CcSEcCtD
Eprosartan—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000699	0.00194	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000697	0.00193	CcSEcCtD
Eprosartan—Abdominal pain—Vincristine—lymphatic system cancer	0.000694	0.00193	CcSEcCtD
Eprosartan—Body temperature increased—Vincristine—lymphatic system cancer	0.000694	0.00193	CcSEcCtD
Eprosartan—Urticaria—Mitoxantrone—lymphatic system cancer	0.00068	0.00189	CcSEcCtD
Eprosartan—Hypersensitivity—Carmustine—lymphatic system cancer	0.000678	0.00188	CcSEcCtD
Eprosartan—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000676	0.00188	CcSEcCtD
Eprosartan—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000676	0.00188	CcSEcCtD
Eprosartan—Vomiting—Bleomycin—lymphatic system cancer	0.00067	0.00186	CcSEcCtD
Eprosartan—Depression—Methotrexate—lymphatic system cancer	0.000666	0.00185	CcSEcCtD
Eprosartan—Rash—Bleomycin—lymphatic system cancer	0.000665	0.00185	CcSEcCtD
Eprosartan—Dermatitis—Bleomycin—lymphatic system cancer	0.000664	0.00184	CcSEcCtD
Eprosartan—Asthenia—Carmustine—lymphatic system cancer	0.00066	0.00183	CcSEcCtD
Eprosartan—Renal failure—Methotrexate—lymphatic system cancer	0.000657	0.00182	CcSEcCtD
Eprosartan—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00065	0.0018	CcSEcCtD
Eprosartan—Hypersensitivity—Vincristine—lymphatic system cancer	0.000647	0.0018	CcSEcCtD
Eprosartan—Haematuria—Methotrexate—lymphatic system cancer	0.000637	0.00177	CcSEcCtD
Eprosartan—Epistaxis—Methotrexate—lymphatic system cancer	0.00063	0.00175	CcSEcCtD
Eprosartan—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00063	0.00175	CcSEcCtD
Eprosartan—Asthenia—Vincristine—lymphatic system cancer	0.00063	0.00175	CcSEcCtD
Eprosartan—Diarrhoea—Carmustine—lymphatic system cancer	0.00063	0.00175	CcSEcCtD
Eprosartan—Nausea—Bleomycin—lymphatic system cancer	0.000626	0.00174	CcSEcCtD
Eprosartan—Asthenia—Mitoxantrone—lymphatic system cancer	0.000614	0.0017	CcSEcCtD
Eprosartan—Dizziness—Carmustine—lymphatic system cancer	0.000608	0.00169	CcSEcCtD
Eprosartan—Diarrhoea—Vincristine—lymphatic system cancer	0.000601	0.00167	CcSEcCtD
Eprosartan—Pharyngitis—Methotrexate—lymphatic system cancer	0.000595	0.00165	CcSEcCtD
Eprosartan—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000585	0.00163	CcSEcCtD
Eprosartan—Vomiting—Carmustine—lymphatic system cancer	0.000585	0.00162	CcSEcCtD
Eprosartan—Dizziness—Vincristine—lymphatic system cancer	0.000581	0.00161	CcSEcCtD
Eprosartan—Rash—Carmustine—lymphatic system cancer	0.00058	0.00161	CcSEcCtD
Eprosartan—Dermatitis—Carmustine—lymphatic system cancer	0.00058	0.00161	CcSEcCtD
Eprosartan—Visual impairment—Methotrexate—lymphatic system cancer	0.000578	0.00161	CcSEcCtD
Eprosartan—Headache—Carmustine—lymphatic system cancer	0.000576	0.0016	CcSEcCtD
Eprosartan—Tinnitus—Methotrexate—lymphatic system cancer	0.000559	0.00155	CcSEcCtD
Eprosartan—Vomiting—Vincristine—lymphatic system cancer	0.000558	0.00155	CcSEcCtD
Eprosartan—Rash—Vincristine—lymphatic system cancer	0.000554	0.00154	CcSEcCtD
Eprosartan—Dermatitis—Vincristine—lymphatic system cancer	0.000553	0.00154	CcSEcCtD
Eprosartan—Headache—Vincristine—lymphatic system cancer	0.00055	0.00153	CcSEcCtD
Eprosartan—Nausea—Carmustine—lymphatic system cancer	0.000547	0.00152	CcSEcCtD
Eprosartan—Vomiting—Mitoxantrone—lymphatic system cancer	0.000544	0.00151	CcSEcCtD
Eprosartan—Rash—Mitoxantrone—lymphatic system cancer	0.000539	0.0015	CcSEcCtD
Eprosartan—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000539	0.0015	CcSEcCtD
Eprosartan—Chills—Methotrexate—lymphatic system cancer	0.000538	0.00149	CcSEcCtD
Eprosartan—Headache—Mitoxantrone—lymphatic system cancer	0.000536	0.00149	CcSEcCtD
Eprosartan—Nausea—Vincristine—lymphatic system cancer	0.000522	0.00145	CcSEcCtD
Eprosartan—Nausea—Mitoxantrone—lymphatic system cancer	0.000508	0.00141	CcSEcCtD
Eprosartan—Back pain—Methotrexate—lymphatic system cancer	0.000505	0.0014	CcSEcCtD
Eprosartan—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000485	0.00135	CcSEcCtD
Eprosartan—Malaise—Methotrexate—lymphatic system cancer	0.000471	0.00131	CcSEcCtD
Eprosartan—Vertigo—Methotrexate—lymphatic system cancer	0.000469	0.0013	CcSEcCtD
Eprosartan—Cough—Methotrexate—lymphatic system cancer	0.000456	0.00127	CcSEcCtD
Eprosartan—Chest pain—Methotrexate—lymphatic system cancer	0.000445	0.00123	CcSEcCtD
Eprosartan—Myalgia—Methotrexate—lymphatic system cancer	0.000445	0.00123	CcSEcCtD
Eprosartan—Arthralgia—Methotrexate—lymphatic system cancer	0.000445	0.00123	CcSEcCtD
Eprosartan—Discomfort—Methotrexate—lymphatic system cancer	0.000439	0.00122	CcSEcCtD
Eprosartan—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000417	0.00116	CcSEcCtD
Eprosartan—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000412	0.00114	CcSEcCtD
Eprosartan—Anorexia—Methotrexate—lymphatic system cancer	0.000406	0.00113	CcSEcCtD
Eprosartan—Hypotension—Methotrexate—lymphatic system cancer	0.000398	0.00111	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000388	0.00108	CcSEcCtD
Eprosartan—Insomnia—Methotrexate—lymphatic system cancer	0.000385	0.00107	CcSEcCtD
Eprosartan—Paraesthesia—Methotrexate—lymphatic system cancer	0.000383	0.00106	CcSEcCtD
Eprosartan—Dyspnoea—Methotrexate—lymphatic system cancer	0.00038	0.00105	CcSEcCtD
Eprosartan—Somnolence—Methotrexate—lymphatic system cancer	0.000379	0.00105	CcSEcCtD
Eprosartan—Dyspepsia—Methotrexate—lymphatic system cancer	0.000375	0.00104	CcSEcCtD
Eprosartan—Decreased appetite—Methotrexate—lymphatic system cancer	0.00037	0.00103	CcSEcCtD
Eprosartan—Fatigue—Methotrexate—lymphatic system cancer	0.000367	0.00102	CcSEcCtD
Eprosartan—Pain—Methotrexate—lymphatic system cancer	0.000364	0.00101	CcSEcCtD
Eprosartan—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000351	0.000975	CcSEcCtD
Eprosartan—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000348	0.000968	CcSEcCtD
Eprosartan—Urticaria—Methotrexate—lymphatic system cancer	0.000339	0.00094	CcSEcCtD
Eprosartan—Abdominal pain—Methotrexate—lymphatic system cancer	0.000337	0.000935	CcSEcCtD
Eprosartan—Body temperature increased—Methotrexate—lymphatic system cancer	0.000337	0.000935	CcSEcCtD
Eprosartan—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000314	0.000872	CcSEcCtD
Eprosartan—Asthenia—Methotrexate—lymphatic system cancer	0.000306	0.000849	CcSEcCtD
Eprosartan—Pruritus—Methotrexate—lymphatic system cancer	0.000302	0.000837	CcSEcCtD
Eprosartan—Diarrhoea—Methotrexate—lymphatic system cancer	0.000292	0.00081	CcSEcCtD
Eprosartan—Dizziness—Methotrexate—lymphatic system cancer	0.000282	0.000782	CcSEcCtD
Eprosartan—Vomiting—Methotrexate—lymphatic system cancer	0.000271	0.000752	CcSEcCtD
Eprosartan—Rash—Methotrexate—lymphatic system cancer	0.000269	0.000746	CcSEcCtD
Eprosartan—Dermatitis—Methotrexate—lymphatic system cancer	0.000268	0.000745	CcSEcCtD
Eprosartan—Headache—Methotrexate—lymphatic system cancer	0.000267	0.000741	CcSEcCtD
Eprosartan—Nausea—Methotrexate—lymphatic system cancer	0.000253	0.000703	CcSEcCtD
